6 analysts have expressed a variety of opinions on SI-BONE (NASDAQ:SIBN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $25.67, along with a high estimate of $27.00 and a low estimate of $24.00. Observing a 1.34% increase, the current average has risen from the previous average price target of $25.33.
Decoding Analyst Ratings: A Detailed Look
The analysis of recent analyst actions sheds light on the perception of SI-BONE by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Saxon | Needham | Maintains | Buy | $27.00 | - |
| David Saxon | Needham | Maintains | Buy | $27.00 | - |
| Matt O'Brien | Piper Sandler | Announces | Overweight | $25.00 | - |
| Drew Ranieri | Morgan Stanley | Raises | Overweight | $26.00 | $25.00 |
| Ross Osborn | Cantor Fitzgerald | Maintains | Overweight | $25.00 | $25.00 |
| Samuel Brodovsky | Truist Securities | Lowers | Buy | $24.00 | $26.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to SI-BONE. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of SI-BONE compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of SI-BONE's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of SI-BONE's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on SI-BONE analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know SI-BONE Better
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Unraveling the Financial Story of SI-BONE
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining SI-BONE's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 21.61% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: SI-BONE's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -28.26%, the company may face hurdles in effective cost management.
Return on Equity (ROE): SI-BONE's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -6.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): SI-BONE's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.76%, the company may face hurdles in achieving optimal financial performance.
Debt Management: SI-BONE's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.23.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.